AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Alland, a seasoned oncologist, has been added to Radiopharm Theranostics’ board as a Non-Executive Director.
- She has had stints at AstraZeneca, Novartis, and other major pharma companies in leadership roles.
- Alland’s onboarding follows another key appointment of Mr. Vittorio Puppo as the company’s COO earlier this month.
A leading player in the pharma industry, Radiopharm Theranostics (ASX:RAD) has appointed Dr. Leila Alland as a Non-Executive Director.
Dr. Alland brings to the table her extensive know-how of oncology drug products. She has served some of the major pharmaceutical firms, including AstraZeneca, Novartis, and Bristol-Myers Squibb in her long career. Her works include involvement in a number of successful drug approvals while working in leadership roles at these places.
Dr. Alland’s associations and academics
Presently, Dr. Alland is associated with clinical-stage precision oncology company PMV Pharmaceuticals in the capacity of Chief Medical Officer. Besides, she is serving the boards of some other biopharma companies. Dr. Alland is also a member of Columbia University's Center for Radiological Research’s Scientific Advisory Council.
New York University School of Medicine is her alma mater. Dr. Alland went to The Children’s Hospital of Philadelphia, The New York Hospital, and other facilities for post-doctoral training in paediatrics and haematology/ oncology. She was served at Albert Einstein College of Medicine as an assistant professor of paediatrics. In recognition of her academic excellence, she was bestowed upon the James S. McDonnell Foundation Scholar Award.
Radiopharm Theranostics’ CEO and MD Riccardo Canevari has hailed Dr. Alland’s inclusion. He said that with her in the company’s board, Radiopharm’s ongoing phase of innovation and growth will witness an uptick.
Also read: Radiopharm Theranostics (ASX:RAD) closes busy March quarter with advanced clinical pipeline
Radiopharm Theranostics - a major player in biotech space
Many analysts are bullish on the biotech sector, particularly radiopharmaceutical products. Radiopharm Theranostics’ focus on diagnostic and therapeutic uses, especially with regards to unmet medical needs, is viewed as the company’s biggest strength.
Earlier this month, Mr. Vittorio Puppo was appointed as the Chief Operating Officer of Radiopharm Theranostics. Mr. Puppo has held various positions in his more than three decades of involvement in the pharma and medical devices industries.
Also read: Meet Vittorio Puppo – Radiopharm Theranostics’ (ASX:RAD) new Chief Operating Officer
RAD shares closed the day’s trade at AU$0.190 on 9 June 2022.
